



US011246850B2

(12) **United States Patent**
Novas et al.

(10) **Patent No.:** **US 11,246,850 B2**
(45) **Date of Patent:** ***Feb. 15, 2022**

(54) **METHODS OF TREATING MULTIPLE SCLEROSIS**

(71) Applicant: **Biogen MA Inc.**, Cambridge, MA (US)

(72) Inventors: **Mark Novas**, Lexington, MA (US); **Rui (Ray) Zhang**, Sharon, MA (US)

(73) Assignee: **Biogen MA Inc.**, Cambridge, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **17/321,788**

(22) Filed: **May 17, 2021**

(65) **Prior Publication Data**

US 2021/0315854 A1 Oct. 14, 2021

Related U.S. Application Data

(63) Continuation of application No. 17/071,740, filed on Oct. 15, 2020, now Pat. No. 11,007,167, which is a (Continued)

(51) **Int. Cl.**

A61K 31/225 (2006.01)

A61K 31/40 (2006.01)

(Continued)

(52) **U.S. Cl.**

CPC **A61K 31/225** (2013.01); **A61K 9/0053** (2013.01); **A61K 9/28** (2013.01); (Continued)

(58) **Field of Classification Search**

CPC **A61K 31/225**

(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,959,389 A 9/1990 Speiser et al.

6,436,992 B1 8/2002 Joshi et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 103732062 A 4/2014

JP 2009-528359 A 8/2009

(Continued)

OTHER PUBLICATIONS

Assessment Report TECIFDERA®, published by the European Medicines Agency, Nov. 26, 2013.

(Continued)

Primary Examiner — Shengjun Wang

(74) *Attorney, Agent, or Firm* — Choate, Hall & Stewart LLP; Brenda Herschbach Jarrell; Tracy L. Vrablik

(57)

ABSTRACT

Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.

27 Claims, 4 Drawing Sheets

